January 3, 2013 / 3:16 PM / 5 years ago

Factbox - Top-selling drugs for ultra-rare diseases

(Reuters) - Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year.

The following are among the top-selling treatments for extremely rare disorders:

Soliris, Alexion Pharmaceuticals (ALXN.O)

- Treatment for a progressive disease that destroys red blood cells and a second condition that damages the kidney and other vital organs.

Forecast 2012 sales: $1.1 billion.

Cerezyme, Sanofi (SASY.PA)

- Drug to help break down fatty clumps that build up in cells in patients with Gaucher disease, damaging the liver, spleen and bones.

Forecast 2012 sales: $830 million

Myozyme, Sanofi

- Treats Pompe disease, an inherited neuromuscular disorder that causes progressive muscle weakness.

Forecast 2012 sales: $580 million

Elaprase, Shire (SHP.L)

- Treatment for Hunter syndrome, a genetic disease that primarily affects males, causing serious physical and mental problems.

Forecast 2012 sales: $495 million

Fabrazyme, Sanofi

- Fabry disease treatment designed to counter damaging symptoms including kidney failure, heart problems and stroke.

Forecast 2012 sales: $352 million

Cinryze, ViroPharma VPHM.O

- Prevents dangerous swelling and painful attacks in people with hereditary angioedema.

Forecast 2012 sales: $330 million

Vpriv, Shire

- Treatment for Gaucher disease.

Forecast 2012 sales: $310 million

Kalydeco, Vertex Pharmaceuticals (VRTX.O)

- For treating a rare form of the lung disease cystic fibrosis in patients with a particular genetic mutation.

Forecast 2012 sales: $260 million

Naglazyme, Biomarin Pharmaceutical (BMRN.O)

- Treatment for Maroteaux-Lamy syndrome, which causes short stature, stiff joints and breathing problems.

Forecast 2012 sales: $233 million

Source: sales figures based on analyst forecasts compiled by Thomson Reuters

Reporting by Ben Hirschler; editing by David Stamp

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below